Diligence memo · auto-generated · as of July 2, 2026
iQure Pharma Inc.
iQure Pharma Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
iQure Pharma Inc. operates in Pharma, based in SKILLMAN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
iQure Pharma Inc. has raised $4.7M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.5M on 2025-09-09.
Most recent recorded round closed around 2025-09-09.
Valuation (modeled)modeled
Provath models iQure Pharma Inc. at approximately $3.8M (range $1.1M–$7.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Seed Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 10 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 53% of Pharma peers (310 compared).
Modeled value ranks above 25% of those peers.
Closest niche peers: Antigenix Therapeutics, Inc., Strategikon Pharma, Inc., Fitness Fingerprint Therapeutics, Inc., NeuroEM Therapeutics, Inc., Persevere Therapeutics Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.